Christopher Bruno, DO
Endocrinology, Diabetes & Metabolism · Collegeville, PANPI 1932385408
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,025 of the $48,418 with a category attached, or 74.4%. 48 manufacturers reported payments, led by AstraZeneca at 49.7% of the total. Reporting peaked in 2021 at $14,902 and has fallen 93.7% since, to $939 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 570 payments — averaging $84.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Dexcom, Inc.$11K
- Merck$6K
- Novo Nordisk$993
- Lilly USA, LLC$890
- Medtronic$614
- plus $5K from 42 others
What the payments were for
- Consulting fees$1,5303%
- Speaking & faculty fees$36,02574%
- Travel & lodging$4681%
- Food & beverage$10,33421%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$22,851
- DEXCOM G6 TRANSMITTER$10,220
- STEGLATRO$5,585
- FREESTYLE LIBRE 3$215
- Kerendia$108
- TEPEZZA$107
How this compares
$48,418 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 745 | $1,045,583 |
| JardianceEmpagliflozin | 374 | $373,250 |
| FarxigaDapagliflozin Propanediol | 306 | $326,177 |
| MounjaroTirzepatide | 204 | $290,874 |
| Tresiba Flextouch U-100Insulin Degludec | 314 | $283,243 |
| JanuviaSitagliptin Phosphate | 226 | $249,626 |
| TrulicityDulaglutide | 75 | $108,233 |
| TradjentaLinagliptin | 86 | $85,515 |
| Novolog FlexpenInsulin Aspart | 283 | $82,311 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 71 | $59,883 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $57,868 |
| SynthroidLevothyroxine Sodium | 522 | $49,904 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $45,276 |
| Humalog Kwikpen U-100Insulin Lispro | 130 | $44,652 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 234 | $37,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $993 | $1,057,337773 claims |
| Boehringer IngelheimJardiance, Tradjenta | $592 | $458,765460 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $890 | $412,223318 claims |
| AstraZenecaFarxiga | $24,082 | $326,177306 claims |
| MerckJanuvia, Janumet Xr | $5,934 | $284,585264 claims |
| AbbVieSynthroid, Armour Thyroid | $255 | $54,308586 claims |
| Johnson & JohnsonInvokana | $40 | $35,41830 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $109 | $6,528709 claims |
| IBSA Pharma Inc.Tirosint | $391 | $5,37314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Collegeville
- Vishal DattaCollegeville$334K
- Sumon AgarwalaCollegeville$78K
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.